Lasa Supergenerics Ltd. · NSE:LASA
Lasa Supergenerics — Investor Presentation (April 2022)
27 slides from Lasa Supergenerics's investor presentation, April 2022
Slide 1: Lasa Supergenerics Limited Investor Presentation
Lasa Supergenerics Limited Investor Presentation
Slide 2: Safe harbor
Safe harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Lasa Supergenerics Limited (the “Company”) solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall
Slide 3: Table of Contents
Table of Contents 01 Chairman’s Message 02 Consolidated Financial Highlights 03 Company Overview 04 Business Overview 05 Growth Strategies
Slide 4: Chairman's Message
Chairman’s Message
Slide 5: Chairman's Message
Chairman’s Message Commenting on the results, Dr. Omkar Herlerkar, ,Chairman & Managing Director, Lasa Supergenerics Ltd. said : The financial for year to date has been in line with our expectation in terms of revenue and profitability. We are glad to focus on new and innovative product which has be
Slide 6: Consolidated Financial Highlights
Consolidated Financial Highlights
Slide 7: Company Overview
Company Overview
Slide 8: Company Overview
Company Overview Leader in Vet APIs Market Market Share Acquired in 2012 with annual About 35% market share in turnover of Rs 1 crore. Currently, 01 stands at Rs ~200 crore Indian animal healthcare industry 08 02 Leader in Catalyst Chemistry Established as a leader in Strong Pipeline of ‘catalyst’ c
Slide 9: Management Team
Management Team Mr. Omkar Herlekar Sumant Kharasambale 04 Ajay Sukhwani 02 Independent Director 06 Chairman & Managing Whole Time Director Director Shivanand Hegde Ekta Gurnasinghani Bachelors of Commerce Hardesh Tolani Handles plant operation, degree from University of Multiple graduation degrees M
Slide 10: Business Overview
Business Overview
Slide 11: Classification of Anthelmintics
Classification of Anthelmintics Piperazines Benzimidazole Imidazo Thiazole Heterocyclics Anthelmintics Amide Nitro Derivative Vinyl Pyrimidines 11
Slide 12: Why Deworming in Cattle / Importance of Deworming in Cattle
Why Deworming in Cattle / Importance of Deworming in Cattle Farm grazing animals such as cow, goat, Possibility of sheep etc. to graze closer to the faecal infection material found in grass Cattle get infected with parasites such as Consequence roundworms, tapeworms and liver fluke Ill effect on the
Slide 13: Strong Product Portfolio
Strong Product Portfolio 01 03 05 07 02 04 06 Albendazole Fenbendazole Nitroxynil Oxfendazole Toldimphos Sodium Providon Iodine Halquinol • Leader in Veterinary API products, Animal feed ingredients, Reagents for therapeutic Use & other API products • No Product Dependency - Top seven products contr
Slide 14: Industry Entry Barriers
Industry Entry Barriers… Backward Integration • Our fully backward integrated API manufacturing model helps us to lower our product cost Catalyst Backed Products • Extensive use of catalysts in API manufacturing helps us to increase our gross profit margins Catalyst Process Patents • Seven catalyst
Slide 15: Process Entry Barriers
Process Entry Barriers… Pressure reactions up to 50 atmospheres High temperature Vacuum handling azetrope separation up to 1-torr Cryogenic Multi-stage reactions fractional up to —75 °c distillation Temperature Column handling chromatography up to 400 °c Membrane filtration & Reverse osmosis Flash &
Slide 16: Competitive Advantages of Backward Integration / Edge Over Others
Competitive Advantages of Backward Integration / Edge Over Others Niche In Backward Integration Basic Petrochemical Basic Intermediate Derivatives [N-1] API Basic Organic Advanced Intermediate Molecule Efficient handling of toxic gases and moisture sensitive compounds 16
Slide 17: Advantages of Catalyst Chemistry
Advantages of Catalyst Chemistry Reduces Time • Plays crucial role in lowering labour costs Generates Less Emission • Cuts down on time cycle • Significantly less by-products • Increases productivity in and effluent discharge same infrastructure, • Curtails toxic threshold Leadings to handsome Ebitd
Slide 18: Our Journey So Far
Our Journey So Far…. Lasa was acquired in April’12 as a 100% subsidiary by Omkar speciality chemicals limited (OSCL) 18
Slide 19: Manufacturing Facilities
Manufacturing Facilities Location Urdhwa, Chiplun Maharashtra Mahad Unit Maharashtra Unit V, Chiplun Maharashtra Unit VI, Chiplun Maharashtra Total Capacity – 4,300 Tonnes Per Annum 19
Slide 20: Product-wise Global Reach
Product-wise Global Reach *Country Albendazole Fenbendazole Oxfendazole Closantel Cyromazine Halquinol Nitroxline PV-I Ricobendazole Toldimphos Oxycloza Australia Bangladesh Brazil Canada China Colombia Egypt Europe Germany Hungary Jordan Kenya Exports Contributes To ~25% of The Revenue *Above are v
Slide 21: Product-wise Global Reach
Product-wise Global Reach *Country Albendazole Fenbendazole Oxfendazole Closantel Cyromazine Halquinol Nitroxline PV-I Ricobendazole Toldimphos Oxycloza Korea Malaysia Brazil Merchant exporters Pakistan Peru Russia Saudi arabia South africa South america Usa West indies Exports Contributes To ~25% o
Slide 22: Certifications / Regulatory Approvals
Certifications / Regulatory Approvals 01 D M Fs & F DA 10 approved products 4 approved pharma zones 02 Pate nt s 7 Process patents filed 03 Sanctions Certified WHO and C-GMP units 22
Slide 23: Process Patents Filed
7 Process Patents Filed Method for the simplified production of Method for the preparation of salicylanilide Process for the preparation of benzimidazole An improved process for the preparation fasciolicide and derivative antiparasitic derivative derivative as anthelmintic agents of triazine derivat
Slide 24: Quality and Assurance
Quality and Assurance • Rm/pm analysis • EU and US GMP training • Finished products analysis • Sop compliance • Finished products analysis • Audit of facility for compliance • In-process checks • In-process counter checks, • Stability studies critical sampling • Instrumental analysis & finished prod
Slide 25: Growth Strategies
Growth Strategies
Slide 26: Growth Strategies
Growth Strategies Expansion & Entry in newer New Product Development geographies • In house catalyst chemistry • Commissioning of a multipurpose expertise enables us to plant with capability to handle introduce new products various high pressure unit • Fully backward integration operations enables u
Slide 27: Thank You
Thank You 540702 LASA LASA:IN LASA.NS For further information, please contact: Company : Investor Relations Advisors : Lasa Supergenerics Ltd. Bridge Investor Relations Pvt. Ltd. CIN: L24233MH2016PLC274202 CIN: U74900MH2016PTC273679 Mr. Hitesh Wadhwani Mr. Amit Sharma Company Secretary amit@bridge-i
Lasa Supergenerics — Investor Presentation (April 2022) on 6ix